Non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: Naringenin supplement (provided by Exir Nano Sina Co.) should consume before dinner and lunch at the dosages of 200 mg/day that divided into two 100 mg capsule per
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: 20 to 65 years old men and women Range of body mass index (BMI) should be between 25 to 35 Kg/m2 Diagnosis of Non-alcoholic fatty liver disease based on sonography by specialist Informed consent for participating in the study
Exclusion criteria
Exclusion criteria: Regular consumption of Non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, corticosteroids, anti-hypertensive agents, lipid-lowering agents and weight-lowering agents in the period of last 3 months Regular consumption of multivitamin-minerals, antioxidants, omega3 supplement at the dosages of more than daily needs and also consumption of probiotic supplements and herbal drinks such as silymarine in the priod of last 3 months Diagnosis of pathological conditions affecting the liver such as viral hepatitis and liver transplantation Past medical history of diabetes, gastrointestinal tract disorders, organs failure, thyroid disorders, kidney diseases, autoimmune diseases, severe mental diseases and several types of malignancies Past medical history of cardiovascular accidents in the period of last 3 months Pregnancy, intention to be pregnant in the next 3 months, breastfeeding and menopause status Being addict, consumption of alcoholic drinks Professional exercise
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum aminoteransferase levels. Timepoint: Before and after the intervention (on the day of 0 and at the end of the next 4 weeks). Method of measurement: Blood levels through special kit.;Insulin resistance index. Timepoint: Before and after the intervention (on the day of 0 and at the end of the next 4 weeks). Method of measurement: Formula.;Hs-CRP. Timepoint: Before and after the intervention (on the day of 0 and at the end of the next 4 weeks). Method of measurement: Blood levels through special kit.;Adiponectin. Timepoint: Before and after the intervention (on the day of 0 and at the end of the next 4 weeks). Method of measurement: Blood levels through special kit.;Neuregulin-4. Timepoint: Before and after intervention (on the day of 0 and at the end of the next 4 weeks). Method of measurement: Blood levels through special kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure. Timepoint: Before and after the intervention (on the day of 0 and at the end of the next 4 weeks). Method of measurement: pressure indicator.;Body mass index. Timepoint: Before and after the intervention (on the day of 0 and at the end of the next 4 weeks). Method of measurement: calculating according to related formula.;Weight. Timepoint: Before and after the intervention (on the day of 0 and at the end of the next 4 weeks). Method of measurement: Digital scale.;Height. Timepoint: Before and after the intervention (on the day of 0 and at the end of the next 4 weeks). Method of measurement: Standard tape meter.;Physical activity score. Timepoint: every two weeks ( on the day 0, 14, 28). Method of measurement: international physical activity questionnaire: short.;Lipid profile. Timepoint: Before and after the intervention (on the day of 0 and at the end of the next 4 weeks). Method of measurement: Blood levels through special kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Javad Hosseinzadeh Attar
Tehran University of Medical Sciences
Outcome results
None listed